Literature DB >> 27755997

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

Marie de Charette1, Aurélien Marabelle2, Roch Houot3.   

Abstract

Downregulation/loss of the antigen presentation is a major immune escape mechanism in cancer. It allows tumour cells to become 'invisible' and avoid immune attack by antitumour T cells. In tumour harbouring properties of professional antigen presenting cells (i.e. tumour B cells in lymphoma), downregulation/loss of the antigen presentation may also prevent direct priming of naïve T cells by tumour cells. Here, we review treatments that may induce/restore antigen presentation by the tumour cells. These treatments may increase the generation of antitumour T cells and/or their capacity to recognise and eliminate tumour cells. By forcing tumour cells to present their antigens, these treatments may sensitise patients to T cell-based immunotherapies, including checkpoint inhibitors.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antigen presentation; Cancer; Checkpoint inhibitors; Immunotherapy

Mesh:

Substances:

Year:  2016        PMID: 27755997     DOI: 10.1016/j.ejca.2016.09.010

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  49 in total

1.  Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.

Authors:  Xiaoguang Wang; Brittany C Waschke; Rachel A Woolaver; Zhangguo Chen; Gan Zhang; Anthony D Piscopio; Xuedong Liu; Jing H Wang
Journal:  Cancer Immunol Res       Date:  2019-06-24       Impact factor: 11.151

Review 2.  Dysfunction of antigen processing and presentation by dendritic cells in cancer.

Authors:  Joanna Bandola-Simon; Paul A Roche
Journal:  Mol Immunol       Date:  2018-04-05       Impact factor: 4.407

Review 3.  Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity.

Authors:  Xiaodan Qin; William D Denton; Leah N Huiting; Kaylee S Smith; Hui Feng
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-07-07       Impact factor: 8.250

4.  Human Gastrointestinal Organoid Models for Studying Microbial Disease and Cancer.

Authors:  Jayati Chakrabarti; Martha B Dua-Awereh; Loryn Holokai; Yana Zavros
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

Review 5.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Blood Adv       Date:  2017-12-08

Review 6.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 7.  Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes.

Authors:  Jasmine A McQuerry; Jeffrey T Chang; David D L Bowtell; Adam Cohen; Andrea H Bild
Journal:  J Mol Med (Berl)       Date:  2017-09-04       Impact factor: 4.599

8.  Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.

Authors:  Dylan J Drakes; Sarwish Rafiq; Terence J Purdon; Andrea V Lopez; Smita S Chandran; Christopher A Klebanoff; Renier J Brentjens
Journal:  Cancer Immunol Res       Date:  2020-03-24       Impact factor: 11.151

9.  Quantitative Proteomic Profiling Reveals Key Pathways in the Anticancer Action of Methoxychalcone Derivatives in Triple Negative Breast Cancer.

Authors:  Catherine C Going; Dhanir Tailor; Vineet Kumar; Alisha M Birk; Mallesh Pandrala; Meghan A Rice; Tanya Stoyanova; Sanjay Malhotra; Sharon J Pitteri
Journal:  J Proteome Res       Date:  2018-09-20       Impact factor: 4.466

Review 10.  The emerging role of epigenetic therapeutics in immuno-oncology.

Authors:  Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2019-09-23       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.